
<http://bio2rdf.org/drugbank:DB00073> a <http://schema.org/Drug> ;
	<http://schema.org/name> "Rituximab" ;
	<http://schema.org/description> "Rituxan is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. Rituximab is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids" ;
	<http://schema.org/url> "https://www.drugbank.ca/drugs/DB00073" ;
	<http://schema.org/doseSchedule> "10 mg Solution form with intravenous route" ;
	<http://schema.org/legalStatus> "approved" ;
	<http://schema.org/manufacturer> "Roche" ;
	<http://schema.org/mechanismOfAction> "The Fab regions of rituximab binds to the CD20 antigen on B lymphocytes, while the Fc domain recruits antibodies and complements to mediate cell lysis." ;
	<http://schema.org/alternateName> "Ig gamma-1 chain C region" ;
	<http://schema.org/sameAs> "https://www.drugbank.ca/drugs/DB00073" .
